木瓜直播

Sana Biotechnology said a type 1 diabetes (T1D) patient without immunosuppression. The company's engineered cell product (UP421) uses a novel hypoimmune technology, and results of the first-in-human trial at 4 weeks showed pancreatic beta cell survival and function.

In a phase IIb/III trial of linsitinib for moderate to severe thyroid eye disease, treatment with the highest dose of the investigational, oral insulin-like growth factor 1 receptor inhibitor at week 24, according to maker Sling Therapeutics.

A database developed by researchers at Mass General Brigham and offers potential alternatives. (Nature Foods)

Investigational atumelnant, a once-daily oral adrenocorticotropic hormone receptor antagonist, in a 12-week phase II study of people with congenital adrenal hyperplasia, said developer Crinetics Pharmaceuticals.

In the phase III OASIS 4 study, investigational elinzanetant caused by adjuvant endocrine therapy in women with or at high risk of developing hormone receptor-positive breast cancer, said Bayer.

North Dakota became the for diabetes or obesity in Affordable Care Act marketplace plans. (Becker's Payer Issues)

And Medicare will now in patients with obesity after last month's FDA approval for that indication. (CNBC)

A novel injectable GLP-1/GIP receptor dual agonist (HRS9531) at week 36 in a phase II trial of Chinese adults with obesity or overweight, said Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics.

A national survey by Orlando Health found that 56% of Americans didn't know that .

The FDA cleared Euroimmun's for free testosterone, said Revvity.

In for anti-obesity drug development, the FDA set an over a year for future products. (Endpoints News)

Although Medicaid reimbursement for increased from 2012 to 2023, less than 100,000 glucagon prescriptions were dispensed in 2023, likely only a fraction of the potential need based on the high-risk population. (JAMA)

Obesity at the time of a pediatric cancer diagnosis was independently , especially for kids with acute lymphoblastic leukemia and central nervous system tumors, a large cohort study found. (Cancer)

Comment